Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of Safety and Efficacy Through Post Market Surveillance for Infanrix, the DTaP Mixed Vaccine.

Next Previous
Trial Profile

Evaluation of Safety and Efficacy Through Post Market Surveillance for Infanrix, the DTaP Mixed Vaccine.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DTaP vaccine (Primary)
  • Indications Diphtheria; Pertussis; Tetanus
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 07 Aug 2009 Actual patient number (1258) added as reported by ClinicalTrials.gov.
  • 28 May 2009 Actual end date changed from Apr 2008 to Jul 2008 as reported by ClinicalTrials.gov.
  • 21 May 2009 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top